about
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano LinfomiAddition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized StudyDiffuse Large B-cell Lymphoma in the elderly: standard treatment and new perspectives.High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis.A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkersLenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi.Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.Overview of alemtuzumab therapy for the treatment of T-cell lymphomas.Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental HPhase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study.Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trialsFollicular lymphomas.Front-line therapy for nonlocalized diffuse large B-cell lymphoma: what has been demonstrated and what is yet to be established.Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study.Follicular Lymphoma: The Management of Elderly Patient.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.Lenalidomide in diffuse large B-cell lymphomas.Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy.XVI. CNS prophylaxis in aggressive lymphomas: for whom and how.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma.[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma.Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphoA comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL).ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
P50
Q28273184-69E06B19-FF07-4A28-96B5-02BDE89EE6F3Q28282827-42D44D8E-4C6F-4CB5-BD06-99A3A0ED5BBFQ30235296-D4F447FE-6E00-4865-83EE-AC5B8423FFF3Q33280731-6CCE199E-8796-4231-B10F-6D98F98D6623Q33378233-0371C607-292D-4B01-90D0-3D5AF4E82CD4Q33391725-626A2806-EAE6-4F1D-8009-8434DA8C3717Q33398019-3D8544CE-F075-49DB-8278-E230E08DD75EQ33408772-179BAE48-6EB4-4160-BFB1-5FE6C936F04BQ33412158-312ADE5B-E5D2-4641-B9CB-920F2374E696Q33414243-2F3F549E-C862-4626-AF87-BD26AF375EA5Q33415354-E571CE98-EEE5-4BD5-9520-E24281AD719BQ33431457-6694EC62-DB3E-4696-A3BE-C0C2BA905730Q33437445-236CC102-1DA9-4C5F-9A6D-9FE391A4F1E7Q34222228-695E7EC1-A0C7-4A0A-A1F8-1B7133C94EC0Q34593816-C4CF3F45-35D7-48F6-85EB-624AFCFE3357Q34598460-4C17F4BC-2864-4A0A-AEA9-1A2CC0186403Q35759705-99185409-E8CD-49E1-8814-14C5166D4A74Q35925639-29E5CF73-15C1-4996-9D32-9B6076F7B083Q36234396-AE2838FD-4CF1-4E0B-95CD-EB38A608E717Q36321170-F157F414-A4D1-4842-B2E6-D8EA1E4B7C78Q37060652-3E835D3D-ABDF-43F5-BB62-44551ABE986CQ37116316-C2711F48-54F1-4DAA-A87E-A4BB1C1E8D4FQ37136999-36419B64-6BC1-4A4C-A749-2B88578C12F4Q37171436-1CA1FFC4-12FF-43AF-B2DE-AF9918046E24Q37316657-AA9500F9-1735-4665-807A-8B378CF32368Q37334956-11660A5E-E878-4CF3-80F3-B1F6C2EF1082Q37577856-E8EF7663-9E38-46DE-8E87-BB7326F54749Q37919520-6C4C76C6-396F-499F-92B6-5A0A4CCB9D63Q38026039-33AE2A09-8548-42A3-9C25-3144A3CE53C0Q38047385-9EAB493F-4B4C-4611-BA7A-FD09F84280CDQ38049331-9E413200-88B2-4CA5-94CD-C00F84D426BBQ38115237-BD36263E-6BF7-49DC-9EB3-D216D51185E3Q38122437-33125C46-E875-4E3E-B252-12B6A9AE1575Q38190105-263B1F1E-8851-4E0C-BD2F-32EC684ECA82Q38209637-AE54B141-1525-45F9-833F-3170458270B7Q38230693-E387B36B-CB7E-4C6A-A441-8FEBF92FF06AQ38238460-7876B0EF-48E1-4BFE-975E-F79D2F84EECDQ38364912-5F0553FF-239E-4231-8139-AFF02D33882CQ38365591-C8ABCBBA-B19A-4E1C-B267-9E9125ABEFB8Q38408414-05B8570C-3D95-492B-B2F4-021AC7B16D2E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Umberto Vitolo
@ast
Umberto Vitolo
@en
Umberto Vitolo
@es
Umberto Vitolo
@nl
type
label
Umberto Vitolo
@ast
Umberto Vitolo
@en
Umberto Vitolo
@es
Umberto Vitolo
@nl
prefLabel
Umberto Vitolo
@ast
Umberto Vitolo
@en
Umberto Vitolo
@es
Umberto Vitolo
@nl
P106
P1153
7003426785
P31
P496
0000-0001-7772-2747